
Martin Ullrich

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/528574/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. Cancers, 2019, 11, 1505.	3.7	120
2	Multimodal Somatostatin Receptor Theranostics Using [⁶⁴ Cu]Cu-/[¹⁷⁷ Lu]Lu-DOTA-(Tyr ³)octreotate and AN-238 in a Mouse Pheochromocytoma Model. Theranostics, 2016, 6, 650-665.	10.0	38
3	HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas. Endocrine-Related Cancer, 2020, 27, 625-640.	3.1	33
4	Three-Dimensional Cell Culture Systems in Radiopharmaceutical Cancer Research. Cancers, 2020, 12, 2765.	3.7	32
5	Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging. Pharmaceuticals, 2020, 13, 272.	3.8	25
6	Impact of Extrinsic and Intrinsic Hypoxia on Catecholamine Biosynthesis in Absence or Presence of Hif2α in Pheochromocytoma Cells. Cancers, 2019, 11, 594.	3.7	24
7	In Vivo Fluorescence Imaging and Urinary Monoamines as Surrogate Biomarkers of Disease Progression in a Mouse Model of Pheochromocytoma. Endocrinology, 2014, 155, 4149-4156.	2.8	16
8	An orthotopic xenograft model for high-risk non-muscle invasive bladder cancer in mice: influence of mouse strain, tumor cell count, dwell time and bladder pretreatment. BMC Cancer, 2017, 17, 790.	2.6	16
9	"Clickable―Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. Journal of Medicinal Chemistry, 2022, 65, 710-733.	6.4	13
10	Personalized drug testing in human pheochromocytoma/paraganglioma primary cultures. Endocrine-Related Cancer, 2022, 29, 285-306.	3.1	12
11	HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models. Cancers, 2021, 13, 385.	3.7	10
12	Diverse effects of phospholipase A2 receptor expression on LNCaP and PC-3 prostate cancer cell growth in vitro and in vivo. Oncotarget, 2018, 9, 35983-35996.	1.8	9
13	Fluorescent mouse pheochromocytoma spheroids expressing hypoxia-inducible factor 2 alpha: Morphologic and radiopharmacologic characterization. Journal of Cellular Biotechnology, 2019, 5, 135-151.	0.5	8
14	Targeting Cyclooxygenase-2 in Pheochromocytoma and Paraganglioma: Focus on Genetic Background. Cancers, 2019, 11, 743.	3.7	6
15	Deuteration <i>versus</i> ethylation – strategies to improve the metabolic fate of an ¹⁸ F-labeled celecoxib derivative. RSC Advances, 2020, 10, 38601-38611.	3.6	6
16	Strain-specific metastatic phenotypes in pheochromocytoma allograft mice. Endocrine-Related Cancer, 2018, 25, 993-1004.	3.1	6
17	Radiolabelled Cyclic Bisarylmercury: High Chemical and inâ€vivo Stability for Theranostics. ChemMedChem, 2021, 16, 2645-2649.	3.2	3
18	Men who stare at bone: multimodal monitoring of bone healing. Biological Chemistry, 2021, 402, 1397-1413.	2.5	3